Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology, NextGen to Offer FFPE Sample Processing and Analysis

NEW YORK (GenomeWeb News) – NextGen Sciences and Expression Pathology will team up to offer protein biomarker services for scientists working with formalin-fixed paraffin-embedded tissue samples, Expression Pathology said today.

The collaborative agreement will allow customers to send their FFPE samples to either company.

Expression Pathology will process samples using its Liquid Tissue MS protein Prep and Director laser micro-dissection technologies. These proteins then will be analyzed for healthy versus diseased or treated versus untreated samples using NextGen’s LC-MS/MS technology.

Immunohistochemistry can take several months to produce antibodies against the proteins, the company said, but the coupled service offering can save time because it does not require antibodies.

“Our combined services will aid in the most challenging task of selecting the appropriate biomarkers for specific drug development programs,” NextGen CEO Mike Pisano said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.